Prophylactic Cranial Irradiation-Related Lymphopenia Affects Progression-Free Survival in Patients with Small Cell Lung Cancer

X. Fan,B. Li,S. Wang,B. Fan,C. Wang,L. Yang,W. Qin,D. Zhang,L. Wang

DOI: https://doi.org/10.1016/j.heliyon.2023.e16483

IF: 3.776

2023-01-01

Heliyon

Abstract:Background: The study aimed to identify the relations of the absolute lymphocyte count (ALC) nadir during prophylactic cranial irradiation (PCI) and patient outcomes in limited-stage small cell lung cancer (LS-SCLC). Methods: We analyzed 268 L S-SCLC patients who underwent PCI from 2012 to 2019. ALC values were collected prior, during, and 3 months post PCI. Kaplan-Meier and Cox regression analyses were performed to assess the relation of ALC to patient prognosis. Two nomograms were developed on the basis of clinical variables for survival prediction. Results: Compared with the ALC before PCI (1.13 x 109 cells/L), the ALC nadir during PCI was significantly reduced by 0.68 x 109 cells/L (P < 0.001) and raised to 1.02 x 109 cells/L 3 months post PCI. Patients with a low ALC nadir during PCI (<0.68 x 109 cells/L) had inferior progression free survival (PFS) (median PFS: 17.2 m vs. 43.7 m, P = 0.019) and overall survival (OS) (median OS: 29.0 m vs 39.1 m, P = 0.012). Multivariate Cox analysis revealed that age, smoking history, clinical stage, and ALC nadir were independent OS (P = 0.006, P = 0.005, P < 0.001 and P = 0.027, respectively), as well as independent PFS predictors (P = 0.032, P = 0.012, P = 0.012 and P = 0.018, respectively). After internal cross-validation, the corrected concordance indices of the predictive nomograms for PFS and OS were 0.637 and 0.663, respectively. Conclusion: LS-SCLC patients with a low ALC nadir during PCI likely have worse survival outcomes. Dynamic evaluation of the ALC during PCI is recommended for LS-SCLC patients.